.VeteransHealth said it will widely cover the expenses for a new Alzheimer's drug after Medicare announced it would not. Leqembi, a $26,500-per-year drug, was approved last month after going through US_FDA's accelerated pathway.
Leqembi, a $26,500-per-year drug, was approved last month after going through the Food and Drug Administration's accelerated pathway. Veterans living with early stages of Alzheimer's can take the drug, manufactured by Eisai and Biogen, which can moderately slow cognitive decline by reducing the protein amyloid.
Results from the drug's testing showed it slowed cognitive decline caused by Alzheimer's by 27% compared to a placebo. It's the first time results indicated that reducing amyloid can benefit patients. Leqembi targets amyloid plaque built up in the brain. While reducing the buildup can be beneficial, it is not a cure for Alzheimer's, per the Hill. The study also found that the drug produced serious side effects, including brain swelling and bleeding.
Without Medicare assistance, seniors would be unlikely to be able to afford the drug given the drug's high prices and coverage restrictions. The FDA's deadline for approval is July 6. If the agency gives the drug full approval, the Centers for Medicare and Medicaid Services would provide broader coverage benefits.Eisai and Biogen previously made an anti-amyloid drug, Aduhelm, which was initially nearly twice as expensive as Leqembi.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Veterans to get coverage of Alzheimer's drug Medicare won't pay forThe Veterans Health Administration said that it intends to pay for a $26,500-a-year experimental Alzheimer's drug that the Centers for Medicare and Medicaid Services has to date declined to cover.
Read more »
Veterans' Health will cover Alzheimer's treatment Leqembi for some patientsVeterans with early Alzheimer's who meet certain VHA criteria can get the treatment covered, according to Eisai.
Read more »
Veterans Health to cover Eisai, Biogen’s new Alzheimer’s drugEisai Co. Ltd. said Tuesday that the Veterans Health Administration will cover Leqembi, the Alzheimer’s disease treatment it developed with Biogen Inc. that...
Read more »
VHA to Cover Cost of Drug for Early Alzheimer’sThe Veterans Health Administration will cover the costs of drug treatment Leqembi, the manufacturer Eisai has announced. Veterans in the early stages of the memory-depleting disease Alzheimer’s who meet VHA criteria will be eligible, Eisai said in a statement. The company is developing the drug with Biogen.
Read more »
More Retiree Health Plans Move Away From Traditional MedicareBob Bentkowski, a retired New York City firefighter, has a rare, painful disease that caused his kidneys to swell almost to the size of basketballs. He needed a transplant, and in the fall of 2021, he found a donor after waiting for years — but he was unsure whether Medicare would cover his surgery. New York City has long provided its retired employees with comprehensive health benefits that pay for most of their Medicare costs. But with his transplant approaching, the city, and a coalition of i
Read more »